company background image
2126

JW (Cayman) Therapeutics SEHK:2126 Stock Report

Last Price

HK$3.30

Market Cap

HK$1.3b

7D

-5.7%

1Y

-79.7%

Updated

26 Sep, 2022

Data

Company Financials +
2126 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

2126 Stock Overview

JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, focuses on developing, manufacturing, and commercializing cell-based immunotherapies for hematological cancers and solid tumors.

JW (Cayman) Therapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for JW (Cayman) Therapeutics
Historical stock prices
Current Share PriceHK$3.30
52 Week HighHK$17.18
52 Week LowHK$3.20
Beta0
1 Month Change-48.03%
3 Month Change-64.13%
1 Year Change-79.71%
3 Year Changen/a
5 Year Changen/a
Change since IPO-85.00%

Recent News & Updates

Shareholder Returns

2126HK BiotechsHK Market
7D-5.7%-10.5%-3.4%
1Y-79.7%-61.3%-25.0%

Return vs Industry: 2126 underperformed the Hong Kong Biotechs industry which returned -61.3% over the past year.

Return vs Market: 2126 underperformed the Hong Kong Market which returned -25% over the past year.

Price Volatility

Is 2126's price volatile compared to industry and market?
2126 volatility
2126 Average Weekly Movement11.0%
Biotechs Industry Average Movement8.4%
Market Average Movement6.3%
10% most volatile stocks in HK Market12.6%
10% least volatile stocks in HK Market3.1%

Stable Share Price: 2126 is more volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: 2126's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.

About the Company

FoundedEmployeesCEOWebsite
2016589James Lihttps://www.jwtherapeutics.com

JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, focuses on developing, manufacturing, and commercializing cell-based immunotherapies for hematological cancers and solid tumors. The company offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of a range of hematological cancers.

JW (Cayman) Therapeutics Fundamentals Summary

How do JW (Cayman) Therapeutics's earnings and revenue compare to its market cap?
2126 fundamental statistics
Market CapHK$1.34b
Earnings (TTM)-HK$937.08m
Revenue (TTM)HK$106.61m

12.7x

P/S Ratio

-1.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
2126 income statement (TTM)
RevenueCN¥96.80m
Cost of RevenueCN¥64.63m
Gross ProfitCN¥32.18m
Other ExpensesCN¥883.06m
Earnings-CN¥850.89m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.07
Gross Margin33.24%
Net Profit Margin-878.98%
Debt/Equity Ratio3.7%

How did 2126 perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is 2126 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 2126?

Other financial metrics that can be useful for relative valuation.

2126 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Sales Ratio vs Peers

How does 2126's PS Ratio compare to its peers?

2126 PS Ratio vs Peers
The above table shows the PS ratio for 2126 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average25.9x
2142 HBM Holdings
6.1x35.3%HK$1.4b
1228 CANbridge Pharmaceuticals
20.8x50.2%HK$1.2b
2181 Mabpharm
43.6xn/aHK$1.5b
6628 Transcenta Holding
31.5x52.4%HK$1.6b
2126 JW (Cayman) Therapeutics
12.7x48.7%HK$1.3b

Price-To-Sales vs Peers: 2126 is good value based on its Price-To-Sales Ratio (12.7x) compared to the peer average (25.9x).


Price to Earnings Ratio vs Industry

How does 2126's PE Ratio compare vs other companies in the HK Biotechs Industry?

Price-To-Sales vs Industry: 2126 is good value based on its Price-To-Sales Ratio (12.7x) compared to the Hong Kong Biotechs industry average (20x)


Price to Sales Ratio vs Fair Ratio

What is 2126's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

2126 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio12.7x
Fair PS Ratio6.9x

Price-To-Sales vs Fair Ratio: 2126 is expensive based on its Price-To-Sales Ratio (12.7x) compared to the estimated Fair Price-To-Sales Ratio (6.9x).


Share Price vs Fair Value

What is the Fair Price of 2126 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 2126's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 2126's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is JW (Cayman) Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


18.7%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 2126 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 2126 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 2126 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 2126's revenue (48.7% per year) is forecast to grow faster than the Hong Kong market (9.7% per year).

High Growth Revenue: 2126's revenue (48.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 2126 is forecast to be unprofitable in 3 years.


Discover growth companies

Past Performance

How has JW (Cayman) Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-12.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 2126 is currently unprofitable.

Growing Profit Margin: 2126 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 2126 is unprofitable, and losses have increased over the past 5 years at a rate of 12.8% per year.

Accelerating Growth: Unable to compare 2126's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2126 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (10.2%).


Return on Equity

High ROE: 2126 has a negative Return on Equity (-32.7%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is JW (Cayman) Therapeutics's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: 2126's short term assets (CN¥1.6B) exceed its short term liabilities (CN¥165.3M).

Long Term Liabilities: 2126's short term assets (CN¥1.6B) exceed its long term liabilities (CN¥127.7M).


Debt to Equity History and Analysis

Debt Level: 2126 has more cash than its total debt.

Reducing Debt: Insufficient data to determine if 2126's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 2126 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 2126 has sufficient cash runway for 2.3 years if free cash flow continues to reduce at historical rates of 41.2% each year.


Discover healthy companies

Dividend

What is JW (Cayman) Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate 2126's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 2126's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 2126's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 2126's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 2126 has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

0.7yrs

Average management tenure


CEO

James Li (58 yo)

6.58yrs

Tenure

Dr. Yiping Li, M.D., also known as James, has been a Partner of KPCB China Fund, which is an affiliate of TDF Capital China II, LP, since 2009. He serves as Co-founder and Executive Chairman at JW (Cayman)...


Leadership Team

Experienced Management: 2126's management team is not considered experienced ( 0.7 years average tenure), which suggests a new team.


Board Members

Experienced Board: 2126's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

SEHK:2126 Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
17 Nov 21SellHK$13,303,498Cheng LiuIndividual1,000,000HK$13.30

Ownership Breakdown

What is the ownership structure of 2126?
Owner TypeNumber of SharesOwnership Percentage
Institutions26,814,2826.5%
Individual Insiders27,923,5886.8%
Private Companies43,403,96010.6%
Public Companies85,463,71020.8%
General Public227,420,79055.3%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.3%.


Top Shareholders

Top 25 shareholders own 43.14% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
17.09%
Bristol-Myers Squibb Company
70,231,140CN¥231.8m0%no data
10.56%
Syracuse Biopharma (Cayman) Ltd
43,403,960CN¥143.2m0%no data
5.06%
Yiping Li
20,786,506CN¥68.6m17.53%no data
3.71%
WuXi AppTec Co., Ltd.
15,232,570CN¥50.3m0%no data
1.74%
Cheng Liu
7,137,082CN¥23.6m0%no data
1.55%
The Vanguard Group, Inc.
6,363,000CN¥21.0m0%no data
0.89%
BlackRock, Inc.
3,653,500CN¥12.1m1%no data
0.82%
Morgan Stanley, Investment Banking and Brokerage Investments
3,355,316CN¥11.1m0%no data
0.56%
Bosera Asset Management Co., Ltd.
2,322,000CN¥7.7m736.76%0.01%
0.46%
GF Fund Management Co., Ltd.
1,879,000CN¥6.2m0%no data
0.17%
Russell Investment Management, LLC
713,000CN¥2.4m0%no data
0.15%
Taikang Asset Management Co., Ltd.
630,000CN¥2.1m0%no data
0.12%
Norges Bank Investment Management
501,067CN¥1.7m0%no data
0.092%
China Asset Management Co., Ltd.
378,255CN¥1.2m759.67%no data
0.068%
Teachers Insurance and Annuity Association-College Retirement Equities Fund
280,500CN¥925.7k79.23%no data
0.031%
PMG Fonds Management AG
129,000CN¥425.7k0%0.02%
0.019%
Dimensional Fund Advisors LP
76,475CN¥252.4k95.19%no data
0.018%
Bruno Walter Finance SA
75,000CN¥247.5k0%0.05%
0.016%
Mercer Global Investments Europe Limited
65,500CN¥216.2k0%no data
0.0092%
American Century Investment Management Inc
38,000CN¥125.4k0%no data
0.0085%
China Universal Asset Management Company Ltd.
35,000CN¥115.5k0%no data
0.004%
Grantham Mayo Van Otterloo & Co. LLC
16,500CN¥54.5k0%no data
0.0025%
Mirae Asset Global Investments Co., Ltd
10,100CN¥33.3k0%no data
0.0015%
Truvalue Asset Management Co.,Ltd.
6,000CN¥19.8k0%no data
0.0011%
BMO Asset Management Corp.
4,395CN¥14.5k0%no data

Company Information

JW (Cayman) Therapeutics Co. Ltd's employee growth, exchange listings and data sources


Key Information

  • Name: JW (Cayman) Therapeutics Co. Ltd
  • Ticker: 2126
  • Exchange: SEHK
  • Founded: 2016
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: HK$1.344b
  • Shares outstanding: 411.03m
  • Website: https://www.jwtherapeutics.com

Number of Employees


Location

  • JW (Cayman) Therapeutics Co. Ltd
  • Building B
  • 5th Floor
  • Shanghai
  • China


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
2126SEHK (The Stock Exchange of Hong Kong Ltd.)YesOrdinary SharesHKHKDNov 2020
JWCT.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDNov 2020

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/26 00:00
End of Day Share Price2022/09/26 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.